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Background: Recent studies have reported associations between a variant allele in a let-7 microRNA
complementary site (LCS6) within the 30untranslated region (30UTR) of KRAS (rs61764370) and clinical outcome in
metastatic colorectal cancer (mCRC) patients receiving cetuximab. The variant allele has also been associated with
increased cancer risk. We aimed to reveal the incidence of the variant allele in a colorectal cancer screening
population and to investigate the clinical relevance of the variant allele in mCRC patients treated with 1st line
Nordic FLOX (bolus 5-fluorouracil/folinic acid and oxaliplatin) +/− cetuximab.
Methods: The feasibility of the variant allele as a risk factor for CRC was investigated by comparing the LCS6 gene
frequencies in 197 CRC patients, 1060 individuals with colorectal polyps, and 358 healthy controls. The relationship
between clinical outcome and LCS6 genotype was analyzed in 180 mCRC patients receiving Nordic FLOX and
355 patients receiving Nordic FLOX + cetuximab in the NORDIC-VII trial (NCT00145314).
Results: LCS6 frequencies did not vary between CRC patients (23%), individuals with polyps (20%), and healthy
controls (20%) (P = 0.50). No statistically significant differences were demonstrated in the NORDIC-VII cohort even if
numerically increased progression-free survival (PFS) and overall survival (OS) were found in patients with the LCS6
variant allele (8.5 (95% CI: 7.3-9.7 months) versus 7.8 months (95% CI: 7.4-8.3 months), P = 0.16 and 23.5 (95% CI:
21.6-25.4 months) versus 19.5 months (95% CI: 17.8-21.2 months), P = 0.31, respectively). Addition of cetuximab
seemed to improve response rate more in variant carriers than in wild-type carriers (from 35% to 57% versus 44% to
47%), however the difference was not statistically significant (interaction P = 0.16).
Conclusions: The LCS6 variant allele does not seem to be a risk factor for development of colorectal polyps or CRC.
No statistically significant effect of the LCS6 variant allele on response rate, PFS or OS was found in mCRC patients
treated with 1st line Nordic FLOX +/− cetuximab.
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The prognosis for patients with metastatic colorectal can-
cer (mCRC) included in clinical trials has increased from
approximately 12 months with 5-fluorouracil monotherapy
to 20–24 months with the addition of newer chemothera-
peutic agents and targeted drugs [1]. Cetuximab and pani-
tumumab, two monoclonal antibodies (moAb) targeting
the epidermal growth factor receptor (EGFR), have proven
to be effective in combination with chemotherapy or as
single agents [2-7]. KRAS mutation is a negative predictive
marker for response to EGFR-targeted therapy and clinical
benefit seems to be restricted to patients with KRAS wild-
type tumors [2-5,8,9]. In the recent NORDIC-VII study,
however, we did not find an improved outcome of adding
cetuximab to first-line oxaliplatin-based chemotherapy in
KRAS wild-type patients [10]. Similar results were found
by the COIN trial [11]. The results of these trials demon-
strate the necessity to explore and validate new biomar-
kers to improve the selection of patients who are likely to
benefit from cetuximab treatment [12]. It was recently
reported that copy number aberrations (CNA) may pro-
vide additional information to mutation status and their
use may potentially further improve the selection of
mCRC patients for EGFR-targeted therapy [13].
MicroRNAs (miRNAs) are a class of highly conserved
22-nucleotides single-stranded RNAs that can act as
trans-acting factors that suppress translation or induce
messenger RNA (mRNA) degradation of target genes
[14]. They are global gene regulators implicated in virtu-
ally all cancer types studied, where they can function
as oncogenes or tumor suppressors [15]. A number of
miRNAs have been reported to be involved in CRC de-
velopment and KRAS regulation, and these may influ-
ence the effect of EGFR-targeted therapy [13,16,17]. An
important miRNA in CRC seems to be miR-143, which,
has been described to be downregulated in CRC [18]
and to inhibit the translation of KRAS mRNA, thereby
altering RAS signaling and inhibiting tumor cell growth
[19]. Pichler et al. found that low miR-143 expression
was an independent negative prognostic factor for can-
cer specific survival in mCRC, and they reported a
decreased PFS in KRAS wild-type mCRC patients treated
with EGFR-targeted agents [16].
The let-7 family of miRNAs plays an important role in
many malignant tumors where they mainly function as
tumor suppressors. Downregulation of let-7 family mem-
bers is observed in multiple carcinomas [20], including
colon cancer [21]. RAS expression was decreased in colon
cancer cell lines after transfection of let-7a-1 miRNA pre-
cursor suggesting that let-7 is involved in regulating
colon cancer cell growth [22]. Let-7 miRNAs downregu-
late RAS after binding to specific sites in the 30 untrans-
lated region (30-UTR) of the KRAS mRNA [23]. A
functional single nucleotide polymorphism has beencharacterized in the let-7 complementary site (LCS6) in
the KRAS 30-UTR mRNA leading to increased expression
of KRAS in vitro and lower let-7 levels in vivo [24].
The LCS6 variant allele is associated with increased
risk of non-small cell lung cancer (NSCLC) in moderate
smokers [24], triple-negative breast cancer in premeno-
pausal women [25], and ovarian cancer in BRCA nega-
tive women from hereditary breast and ovarian cancer
syndrome families [26]. Moreover, the LCS6 variant al-
lele is enriched in BRCA negative double primary breast
and ovarian cancer patients [27]. One study failed to find
an association between the LCS6 variant allele and spor-
adic or familial ovarian cancer risk [28]. A recent study
confirms the importance of the LCS6 variant allele in
postmenopausal ovarian cancer patients and demon-
strates that it is a biomarker of poor outcome in this dis-
ease, probably due to platinum resistance [29]. The
LCS6 variant allele is also associated with reduced sur-
vival in oral cancer [30]. On the contrary, Smits et al.
found that early-stage CRC patients with the LCS6 vari-
ant allele had better outcome [31], whereas Ryan et al.
recently reported the LCS6 variant allele to be associated
with reduced risk of mortality in late-stage CRC [32].
We determined the frequency of the LCS6 variant
allele in a Norwegian case–control study, the KAM
cohort, consisting of CRC patients, individuals with
polyps in the large intestine, and healthy controls, to in-
vestigate the feasibility of the variant allele as a risk fac-
tor for CRC development.
Three studies have reported conflicting results regard-
ing the relationship between the LCS6 variant allele and
clinical outcome in mCRC patients receiving cetuximab
[33-35]. In this work we have studied if the LCS6 variant
allele was associated with clinical outcome in NORDIC-
VII, a randomized phase III trial where Nordic FLOX
(bolus 5-fluorouracil/folinic acid and oxaliplatin) was
given with or without cetuximab as first-line treatment
in mCRC [10].
Methods
NORDIC-VII
In the NORDIC-VII trial (NCT 00145314), patients with
mCRC were randomized to receive first-line standard
Nordic FLOX (bolus 5-fluorouracil/folinic acid and oxa-
liplatin) (arm A), cetuximab and Nordic FLOX (arm B),
or cetuximab combined with intermittent Nordic FLOX
(arm C) [10]. Primary endpoint was progression-free
survival (PFS), overall survival (OS) and response rate
were secondary endpoints. Mutation analysis of KRAS
and BRAF were performed. Cetuximab did not add sig-
nificant benefit to Nordic FLOX and KRAS mutation
was not predictive for cetuximab effect.
DNA from a total of 535 of the 566 patients in the
intention to treat population was evaluable for LCS6
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five were due to low DNA concentration, seven to un-
determined results, and 19 samples were not available.
There were 180 patients in arm A and 355 patients in
arms B and C evaluable for response and survival ana-
lyses. Response status was evaluated according to the
RECIST version 1.0 criteria and was assigned to patients
with complete or partial remission with changes in
tumor measurements confirmed by repeat studies per-
formed no less than 4 weeks after the criteria for re-
sponse were first met (minimum interval of 8 weeks –
4 cycles) [36]. The study was approved by the national
ethics committees and governmental authorities in each
country and was conducted in accordance with the
Declaration of Helsinki. All patients provided written
informed consent.
KAM cohort
The KAM cohort is based on the screening group of the
Norwegian Colorectal Cancer Prevention study (The
NORCCAP study) (NCT00119912) [37] and CRC cases
(not evaluated for metastases) from Telemark Hospital
and Oslo University Hospital. Evaluable blood samples
for LCS6 genotyping were obtained from 197 CRC
patients, 1060 individuals with polyps in the large intes-
tine, and 358 healthy controls. All participants in the
KAM study provided written informed consent. The
project was approved by the Ethics Committee REK
South-East, Norway (Regional komite for medisinsk og
helsefaglig forskningsetikk Sør-Øst).
LCS6 genotyping
The single nucleotide variant allele rs61764370 is located
in the let-7 complementary site 6 (LCS6) of the KRAS
30 UTR. The LCS6 genotype was determined using an
in-house TaqManW allelic discrimination assay on a
Sequence Detection System ABI 7500. Forward and
reverse primer sequences are TGTGCCACTACACT
CAACTAATTTTTG and TGGTAGGCACTCAATAAA
TATTTGCT respectively. Probes were labeled VIC
(wild-type) and 6FAM (variant type) with sequences VIC-
TGACCTCAAGTGATTCA-MGB and 6FAM-AAGTG
ATGCACCCACCTT-MGB (Applied Biosystems). A
BLAST search of primer and probe sequences was per-
formed with adequate specificity for the locus of interest.
The assay was performed in 10 μL reactions containing
1 x Mastermix, 200 nM of each probe, 900 nM of each
primer, and 20–40 ng of genomic DNA extracted from
peripheral blood. Cycling conditions were according
to the TaqManW Genotyping Assay Protocol: 50°C for
2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s
and 60°C for 1 min. Genotype calling was performed
semi-automated using the Sequence Detection Softwarev1.3 (Applied Biosystems). The analyses were performed
in duplicate.
Statistical analyses
As a consequence of the low frequency of the homozy-
gous LCS6 G-allele, the G/T and G/G genotypes were
collapsed in the analyses. For the prognostic analyses all
three arms (arms A, B and C) were analyzed together.
For the predictive analyses arm A was compared to arms
B and C together. The association of the LCS6 genotype,
KRAS and BRAF mutation status was analyzed by the
chi-square test. The association between the LCS6 geno-
type and tumor response was analyzed by binary logistic
regression for the prognostic and predictive analyses. OS
and PFS times were estimated using the Kaplan-Meier
method. The associations of the LCS6 genotype and PFS
and OS were analyzed by Cox’s proportional hazard re-
gression model. The value of LCS6 as a predictive mar-
ker of cetuximab effect was analyzed by including an
interaction term in the models. The distribution of geno-
types in the NORDIC-VII study and the KAM cohort
were tested for Hardy-Weinberg equilibrium [38]. The
distribution of the LCS6 genotype in the CRC patients,
the individuals with polyps and the healthy controls
from the KAM cohort was analyzed by the chi-square
test. P < 0.05 was considered statistically significant. All
p-values were two-sided. The statistical analyses were
performed using Statistical Package for Social Sciences,
version 18.0. (SPSS Chicago, IL).
Results
LCS6 variant allele and CRC risk
The frequency of the LCS6 variant allele in the KAM co-
hort was 20% in healthy controls (70/358; 2 homozygous
and 68 heterozygous), 20% in individuals with polyps
(209/1060; 16 homozygous and 193 heterozygous), and
23% in CRC patients (46/197; 1 homozygous, 45 hetero-
zygous) (P = 0.5) (Table 1). The distribution of geno-
types was in Hardy-Weinberg equilibrium (P = 0.34,
0.19, and 0.22 for healthy controls, individuals with
polyps, and CRC patients, respectively).
Characteristics of patients in the NORDIC-VII study
There were 84 (16%) carriers of the variant allele in the
NORDIC-VII cohort. Three patients were homozygous,
81 heterozygous. The distribution of genotypes were in
Hardy-Weinberg equilibrium (P = 0.75) and the distri-
butions of the variant allele were similar in arms A,
B, and C with frequencies of 14% (26/180), 18% (33/181),
and 14% (25/174), respectively (Table 2). LCS6 status and
KRAS mutation status were available from 471 patients,
of which 183 (39%) were KRAS mutated. Patients with
Table 1 LCS6 genotype frequencies in controls,
individuals with polyps and CRC patients
Study population Genotype Frequency
Controls Wild-type (TT) 288/358 (80%)
Variant (TG/GG) 70/358 (20%)
Individuals with polyps Wild-type (TT) 851/1060 (80%)
Variant (TG/GG) 209/1060 (20%)
CRC patients Wild-type (TT) 151/197 (77%)
Variant (TG/GG) 46/197 (23%)
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(155/392) as compared to 35% (28/79) in patients with
the variant allele. LCS6 status and BRAF mutation status
were available from 435 patients, of which 53 (12%) were
BRAF mutated. For patients with LCS6 wild-type, the fre-
quency of BRAF mutation was 12% (45/361) as compared
to 11% (8/74) in patients with the LCS6 variant allele.
There was no significant association between KRAS or
BRAF mutation status and LCS6 genotype (P = 0.53 and
0.71, respectively).Response rate and survival
There was no significant difference in response rates in
LCS6 wild-type of which 46% (208/451) responded, com-
pared to 50% (42/84) in patients with the LCS6 variant
allele (P = 0.55). Numerically increased median PFS and
OS were found in patients with the LCS6 variant allele
(8.5 months (95% CI: 7.3-9.7 months) and 23.5 months
(95% CI: 21.6-25.4 months), respectively) compared to
LCS6 wild-type (7.8 months (95% CI: 7.4-8.3 months) and
19.5 months (95% CI: 17.8-21.2 months), respectively),Table 2 Patient characteristics in the NORDIC-VII study
LCS6 wild-type (N=451) LCS6 variant (N=84)
Arm A B C A B C
N 154 148 149 26 33 25
% 86 82 86 14 18 14
Age, years
Median 60.4 60.8 63.7 63.8 60.6 62.3
Min 29.9 24.1 33.1 37.1 38.0 36.3
Max 74.8 74.4 74.9 74.7 73.7 74.0
Sex (%)
Male 56 63 60 46 70 76
Female 44 37 40 54 30 24
Location primary tumor (%)
Colon 55 53 66 65 61 52
Rectum 45 47 34 35 39 48although not statistically significant (Log rank P = 0.16
and 0.31, respectively; Figures 1 and 2).
Predictive analyses for benefit of cetuximab treatment
Addition of cetuximab to FLOX seemed to improve
treatment response more in patients with the LCS6 vari-
ant allele (35% in arm A versus 57% in arms B and C)
than in wild-type carriers (44% in arm A versus 47% in
arms B and C), but the difference was not statistically
significant (interaction P = 0.16, Figure 3). Median PFS
and OS were similar in arms B + C (8.5 months
(95% CI: 7.0-10.0 months) and 23.5 months (95% CI:
19.9-27.1 months), respectively) as compared to arm A
(7.7 months (95% CI: 3.8-11.6 months) and 22.3 months
(95% CI: 13.2-31.4 months), respectively) in patients
with the LCS6 variant allele (interaction P = 0.63 and
0.50, respectively, Table 3).
Discussion
The frequency of the LCS6 variant allele in a Norwegian
cohort was similar in healthy controls, individuals with
polyps, and CRC patients. These results do not support
the LCS6 variant allele as a candidate risk factor for de-
velopment of colorectal polyps or CRC. The frequency
of the LCS6 variant allele varies across geographic popu-
lations, with European populations exhibiting the variant
allele most frequently [24,31,32,39,40]. The frequency of
the LCS6 variant allele was 16% in 535 genotyped
patients in the NORDIC-VII cohort, which is consistent
with a recent study which analyzed 734 CRC cases from
the Netherlands [31]. Interestingly, the frequency of the
variant allele in mCRC patients in the NORDIC-VII co-
hort is significantly lower than in the CRC patients from
the KAM cohort (P = 0.02). A possible explanation
could be that the NORDIC-VII cohort consists of a
more heterogeneous population from the NordicFigure 1 Kaplan-Meier progression-free survival by LCS6 wild-
type (N = 451) and LCS6 variant (N = 84), log rank P = 0.16.
Figure 2 Kaplan-Meier overall survival by LCS6 wild-type
(N = 451) and LCS6 variant (N = 84), log rank P = 0.31.
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of a homogenous Norwegian population. Another pos-
sible explanation could be that CRC patients with the
LCS6 wild-type have a greater tendency to metastasize.
A recently published study found that early-stage CRC
cases with the LCS6 variant had improved survival [31].
Another study reported that the LCS6 variant was asso-
ciated with a reduced risk of mortality in late-stage CRC
[32]. Numerically increased median PFS and OS were
found in patients with the LCS6 variant allele when
compared to LCS6 wild-type carriers, but the differences
were not statistically significant at the 5% level and we
cannot conclude that mCRC patients with the variant
allele belong to a favorable prognostic group. Further-
more, the difference in treatment response of adding
cetuximab was larger, albeit not statistically significant,
in patients with the LCS6 variant. There was a non-
significant trend of increased response rate for patientsFigure 3 Confirmed response by LCS6 genotype and treatment.with the LCS6 variant allele when treated with
5-fluorouracil/oxaliplatin and cetuximab compared to
5-fluorouracil/oxaliplatin alone. The trend of numerically
increased PFS, OS and response rate was also observed
independent of KRAS mutation status and in KRAS and
BRAF wild-type patients, but none of the findings proved
statistically significant. Thus, any potential predictive ef-
fect of the LCS6 variant allele is likely to be too small to
be demonstrated with the patient sample available from
the NORDIC-VII study. The NORDIC-VII cohort has
limitations for studies of biomarkers predictive of cetuxi-
mab effect, as cetuximab did not add significant benefit
to the Nordic FLOX regimen. Also, the number of
patients with the LCS6 variant allele is relatively small,
and the analyses of LCS6 as a predictive marker thus have
low power.
Zhang et al. demonstrated that of 67 KRAS wild-type
mCRC patients, there was a higher response rate and a
trend of longer PFS and OS in patients with LCS6 vari-
ant allele (N=12) compared to patients with LCS6 wild-
type (N=55) when treated with cetuximab monotherapy
[34]. Contrary, another study on 121 BRAF wild-type
mCRC patients who underwent salvage cetuximab –
irinotecan therapy, of which 58 were KRAS mutated,
reported that patients with LCS6 variant allele (N=34)
had shorter PFS and OS compared to LCS6 wild-type
(N=87) [33]. Similar results were reported by Winder
et al. who found mCRC patients with mutant KRAS and
LCS6 variant allele to have shorter PFS when treated
with irinotecan and cetuximab [35]. The conflicting
results in these studies suggest that the chemotherapy
backbone may play a role, and that the LCS6 variant
allele have different predictive values in mCRC patients
treated with cetuximab alone or in combination with
5-fluorouracil/oxaliplatin than in patients treated with
cetuximab in combination with irinotecan [41,42].
Table 3 Progression-free survival and overall survival by LCS6 genotype and treatment
LCS6 genotype N Arm Median months 95% CI Interaction P value
Progression-free survival
Wild-type 154 A 7.9 7.2-8.5 0.63
297 B+C 7.7 7.2-8.3
Variant 26 A 7.7 3.8 – 11.6
58 B+C 8.5 7.0-10.0
Overall survival
Wild-type 154 A 20.4 16.5 – 24.2 0.50
297 B+C 18.9 16.9 – 20.9
Variant 26 A 22.3 13.2 – 31.4
58 B+C 23.5 19.9 – 27.1
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induced miRNA transcriptome changes in drug-sensitive
and drug-resistant CRC cell lines [17]. The set of differ-
entially expressed miRNAs in the two cell lines (one sen-
sitive and the other resistant) was almost entirely not
overlapping. These data suggest that different responses
to cetuximab are associated with different sets of miR-
NAs and thereby different molecular signaling. Interest-
ingly, 67% of the differentially expressed miRNAs were
involved in cancer, including CRC, whereas 19 miRNA
targets had previously been reported to be involved in
the cetuximab pathway and CRC. Based on their results,
they suggest downregulation of let-7b and let-7e and the
upregulation of miR-17* to be associated with cetuximab
resistance [17]. Although these miRNAs were generated
from cell studies, they illustrate that miRNAs may be
promising predictive markers of cetuximab response to
be further studied in mCRC patients.
We have only investigated one miRNA binding site
polymorphism in this study, representing a small piece
in a large puzzle of polymorphisms in the miRNA path-
way. Future research on miRNA pathway polymorph-
isms as potential prognostic and/or predictive markers
in mCRC should ideally include an integrated approach
using bioinformatical tools combined with biological
data to get a comprehensive understanding of the role
and functions of miRNA polymorphisms and cetuximab
response.
Conclusions
The LCS6 variant allele does not seem to be a risk factor
for development of colorectal polyps or CRC. No prog-
nostic effect of the LCS6 variant allele was demonstrated
in the NORDIC-VII cohort. No predictive effect of the
LCS6 variant allele on response rate, PFS or OS when
cetuximab is given in combination with 5-fluorouracil/
oxaliplatin in the first-line treatment of mCRC patients
could be proven. Although our study has a larger samplesize than previously published studies, the sample size in
the subgroup with the variant allele is still too low to ob-
tain sufficient power to reliably conclude in subgroups
based on treatment and genotype. Studies with larger
sample size and with stratification of molecular sub-
groups and chemotherapy backbone are necessary to re-
veal if the LCS6 variant allele could be clinically useful
when treating mCRC patients in the future.Competing interests
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